Data from Dual-Acting Oral Biologic Show Promising Safety and Efficacy Profile

Study to Evaluate SOR102, a Novel Oral Dual-Acting Antibody Targeting TNF⍺ and IL-23 (p19) for Inflammatory Bowel Disease

Series A Financing Funds Multiple Programs to Phase 1 and IND stage